RASSF1 promoter hypermethylation is also reported in osteosarcoma, breast cancer, upper aerodigestive tract cancer, glioma, clear cell carcinoma of the kidney, urothelial carcinoma, thyroid carcinoma, and neuroblastoma [34]. This evidence concerns the gene RASSF1 and clear cell renal carcinoma.